A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered ALS-008176 Regimens in Adult Subjects Hospitalized with Respiratory Syncytial Virus - A Phase 2b study for adults with Respiratory Syncytial Virus.

Janssen-Cilag International NV0 个研究点目标入组 90 人开始时间: 2016年8月11日最近更新: 2018年11月6日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Janssen-Cilag International NV
入组人数: 90

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Each potential subject must satisfy all of the following criteria to be enrolled in the study:
•1. Men or women =50 years of age, defined at the time of randomization.
•2. Hospitalized (or in emergency room prior to hospitalization) at the time of randomization and unlikely to be discharged for the first 24 hours after randomization.
•3. Diagnosed with RSV infection based on polymerase chain reaction (PCR)-based assay due to the low viral loads in adults with or without co-infection with another respiratory pathogen (eg, influenza, human metapneumovirus, or bacteria).
•4. Has been, or will be, admitted to the hospital with an acute respiratory illness with signs and symptoms consistent with a viral infection (eg, fever, cough, nasal congestion, runny nose, sore throat, myalgia, lethargy, shortness of breath, or wheezing) with onset =5 days from the anticipated time of randomization.
•5. With the exception of the RSV disease, medically stable on the basis of medical history, physical examination, vital signs, and 12-lead ECG performed at screening. If there are abnormalities, they must be consistent with the underlying illness in the study population. This determination must be recorded in the subject’s source documents and initialled by the investigator.
•6. Medically stable on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry, haematology, or urinalysis are outside the normal reference ranges, the subject may be included only if the investigator judges the abnormalities or deviations from normal do not pose an unacceptable risk to the subject, are not clinically significant, or are appropriate and reasonable for the population under study. This determination must be recorded in the subject’s source documents and initialled by the investigator. A single repeat laboratory evaluation is allowed for eligibility determination.
•7. Must sign an ICF (or their legally acceptable representative must sign) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.
•8. A woman must have a negative serum ß-human chorionic gonadotropin at screening.
•9. Contraceptive use by women should be consistent with local regulations regarding the use of contraceptive methods for subjects participating in clinical studies.
•A woman must be of non-child bearing potential defined as either:
•Postmenopausal: a postmenopausal state is defined as no menses for 12 months without an alternative medical cause and a serum follicle-stimulating hormone level in the postmenopausal range (>40 IU/L or mIU/mL), OR
•Permanently sterile: permanent sterilization methods include hysterectomy, bilateral salpingectomy, bilateral tubal occlusion/ligation procedures (without reversal operation), and bilateral oophorectomy.
•10. Contraceptive use by men should be consistent with local regulations regarding the use of contraceptive methods for subjects participating in clinical studies.
•During the study and for a minimum of 1 spermatogenesis cycle (defined as approximately 90 days) after receiving the last dose of study drug, a man:
•Who is sexually active with a woman of childbearing potential must agree to use a barrier method of contraception (e.g., condom with spermicidal foam/gel/film/cream/suppository)
•Who is sexually active with a pregnant woman must use a condom
•Must agree not to donate sperm
•11. Female partners of men must either be surgically sterili

排除标准

•4.2. Exclusion Criteria
•Any potential subject who meets any of the following criteria will be excluded from participating in the study:
•1. Subjects who are not expected to survive for more than 48 hours.
•2. Subjects who have had major thoracic or abdominal surgery in the 6 weeks prior to randomization.
•3. Subjects who are considered by the investigator to be immunocompromised within the past 12 months, whether due to underlying medical condition (e.g., malignancy or genetic disorder) or medical therapy (e.g., medications, chemotherapy, radiation, stem cell or solid organ transplant).
•4. Subjects with a known history of human immunodeficiency virus (HIV) or chronic viral hepatitis.
•5. Subjects with ALT =3 times the upper limit of normal (ULN) AND bilirubin =2×ULN (direct >35%) OR ALT =5×ULN at screening.
•6. Subjects undergoing peritoneal dialysis, haemodialysis, or hemofiltration or with an estimated glomerular filtration rate (GFR, determined by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation) of <30 mL/min.
•7. Known allergies, hypersensitivity, or intolerance to ALS-008176 or its excipients (refer to the IB).1
•8. Subjects who are anticipated to be treated or who are being treated with other agents with potential antiviral activity against RSV (e.g., ribavirin, intravenous immunoglobulin, palivizumab). Medications treating the sequelae of the RSV infection or any concurrent illness are permitted if not otherwise excluded (see Section 8).
•9. Subjects unwilling to undergo mid-turbinate nasal swab procedures or with any physical abnormality which limits the ability to collect regular nasal specimens.
•10. Subjects unable to take medications enterally or with a known gastrointestinal-related condition that is considered by the sponsor or investigator to be likely to interfere with study drug absorption.
•11. Women who are pregnant or breastfeeding.
•12. Men who plan to father a child while enrolled in this study or within 90 days after the last dose of study drug.
•13. Subjects taking any disallowed therapies as noted in Section 8 before the planned first dose of study drug.
•14. Subjects who received an investigational drug, an investigational vaccine, or used an invasive investigational medical device within 30 days or 5 half-lives (whichever is longer) before the planned first dose of study drug or is currently enrolled in an investigational study.
•15. Subjects with any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.

研究者

发起方

Janssen-Cilag International NV

相似试验

进行中（未招募）

1 期

A controlled clinical trial to study RM-131 (relamorelin) in patients with vomiting symptoms and diabetic gastroparesisVomiting symptoms in patient with moderate to severe diabetic gastroparesisMedDRA version: 17.1Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disorders

EUCTR2014-005623-27-BERhythm Pharmaceuticals, Inc.395

进行中（未招募）

1 期

A double-blind, placebo-controlled Clinical Trial to evaluate the Safety and Efficacy of JNJ-64304500 in patients with Moderately to Severely Active Crohn’s Disease

EUCTR2016-000634-21-HUJanssen-Cilag International NV693

进行中（未招募）

1 期

A Phase 2b study for adults hospitalized with Respiratory Syncytial Virus.Respiratory Syncytial Virus Infection

EUCTR2016-001653-40-BGJanssen-Cilag International NV49

进行中（未招募）

1 期

A study to investigate the effects of lumicitabine (JNJ-64041575) in hospitalized adults infected with human metapneumovirusHuman metapneumovirus infectionMedDRA version: 20.0Level: PTClassification code 10066226Term: Metapneumovirus infectionSystem Organ Class: 10021881 - Infections and infestations

EUCTR2017-001696-22-ESJanssen-Cilag International NV180

进行中（未招募）

1 期

EUCTR2017-001696-22-SEJanssen-Cilag International NV180